Skip to content

Construction and application of remote intervention scheme for patients with metabolism-related fatty liver based on time-sensitive incentive theory

Construction and application of remote intervention scheme for patients with metabolism-related fatty liver based on time-sensitive incentive theory

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096119
Enrollment
Unknown
Registered
2025-01-17
Start date
2024-08-08
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

intervention group:Wechat Group of diet and exercise management + Tencent conference lecture based on timeliness incentive theory
control group:Conventional WeChat group of diet and exercise management + tencent meeting lecture

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. MAFLD diagnostic criteria, ultrasound diagnosis of hepatic steatosis combined with diabetes, overweight or obesity (BMI>=25); Or at least two of the following metabolic abnormalities: (1) Waist circumference greater than 102/88 cm in men and women, respectively; Blood pressure =130/85 mmHg or being treated for hypertension; (2) Plasma triglyceride =150 mg/dl; (3) Plasma high density lipoprotein (HDL) -cholesterol 2.5; 2. Patient age >18 years old; 3. without neurological disease, can effectively communicate, cooperate with investigators; 4. Can use wechat, sports bracelet and other electronic devices, have reading comprehension ability; 5. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. motor system injury or movement taboo; 2. Patients with diseases of the heart, brain, lungs and other vital organs; 3. other diseases affecting the implementation of dietary prescriptions; 4. Patients taking drugs that affect blood lipids and enzymes during the test; 5. in hospitalized patients with seere MAFLD and merging other patients with liver diseases (hepatitis, liver cirrhosis, liver cancer, etc.).

Design outcomes

Primary

MeasureTime frame
fatty liver improvement;analyses of health behaviors;

Secondary

MeasureTime frame
BMI;biochemical indices;analyses of health behaviors;

Countries

China

Contacts

Public ContactYing Chen

The Second Affiliated Hospital of Chongqing Medical University

300492@hospital.cqmu.edu.cn+86 138 8335 6657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026